Advertisement
Advertisement
U.S. Markets open in 57 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.2400-0.1300 (-2.97%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3700
Open4.4600
Bid3.3400 x 1400
Ask4.3800 x 1000
Day's Range4.0500 - 4.4600
52 Week Range3.9400 - 10.5000
Volume12,655
Avg. Volume27,140
Market Cap29.418M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-0.2000
Earnings DateApr 26, 2022 - May 02, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
  • GlobeNewswire

    Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes

    Recently presented data further demonstrate steroid challenge is highly predictive of IOP response post-FAc regardless of steroid choiceATLANTA, May 12, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that the phase 4 PALADIN study confirmed the benefit of using a prior course of cort

  • Zacks

    Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates

    Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.87% and 8.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Alimera Sciences Reports First Quarter 2022 Results

    Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021U.S. Net Revenue Increased 23% vs. First Quarter of 2021U.S. End User Demand Up 25% vs. First Quarter of 2021 ATLANTA, May 09, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter

Advertisement
Advertisement